MARKET

PASG

PASG

Passage Bio, Inc.
NASDAQ
8.90
-0.61
-6.41%
After Hours: 8.90 0 0.00% 16:10 02/09 EST
OPEN
9.51
PREV CLOSE
9.51
HIGH
10.37
LOW
8.86
VOLUME
75.94K
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
5.12
MARKET CAP
28.29M
P/E (TTM)
-0.6149
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PASG last week (0202-0206)?
Weekly Report · 15h ago
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Doximity (DOCS) and Molina Healthcare (MOH)
TipRanks · 3d ago
Weekly Report: what happened at PASG last week (0126-0130)?
Weekly Report · 02/02 09:48
Passage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
TipRanks · 01/29 21:35
Weekly Report: what happened at PASG last week (0119-0123)?
Weekly Report · 01/26 09:48
Weekly Report: what happened at PASG last week (0112-0116)?
Weekly Report · 01/19 09:52
Passage Bio Highlights PBFT02 Progress and Extended Cash Runway
TipRanks · 01/12 12:37
Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases
Reuters · 01/12 12:35
More
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Webull offers Passage Bio Inc stock information, including NASDAQ: PASG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PASG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PASG stock methods without spending real money on the virtual paper trading platform.